UPDATE 1-Lilly cancer drug improves survival, raises blood clot risk -FDA

WASHINGTON, July 7 (Reuters) - Eli Lilly & Co.'s experimental lung cancer drug necitumumab improved overall survival by an average of 1.6 months but also increased the risk of sometimes fatal blood clots, according to a preliminary review by the U.S. Food and Drug Administration.